samedan logo
 
 
spacer
home > pmps > winter 2017 > breathing space
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Breathing Space

Inhalation technology is considered to be one of the most feasible administration options for patients as, unlike other methods of application, it is painless and flexible. This drug delivery technology is gaining increasing importance for the treatment of asthma, chronic obstructive pulmonary disease (COPD), respiratory allergies and cystic fibrosis, among others. Due to the large surface area presented by the respiratory tract, this route expedites drug absorption and onset action, while allowing for smaller doses to be administered. It has also been found to increase patient compliance.

However, there are various disadvantages associated with inhalation technology such as:
  • Persistent drug irritation
  • The risk of toxic particles affecting the lungs
  • Drug stability issues
  • Deposition of aerosolised particles in the oropharyngeal area and within the upper airway


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With over 10 years of experience in market research and consulting, Rajiv Kalia is Associate Director of Healthcare at MarketsandMarkets. He endeavours to constantly track and analyse healthcare market developments and research areas for the team. Prior to joining MarketsandMarkets, he has worked with WNS Global Services and Smartanalyst India Private Limited in similar areas.

With over five years of experience in healthcare market research and consulting, Ruchika Kakarya is a Senior Research Analyst of Healthcare at MarketsandMarkets. She specialises in market size estimations and building forecast models. Prior to joining MarketsandMarkets, Ruchika worked with WNS Global Services and Global Data Research Center in similar areas.

Experienced in market research and report writing, Pooja Ganguly is a Research Associate of Healthcare at MarketsandMarkets. With her strong technical, analytical knowledge, she provides business and market analysis solutions with detailed attention on forecasting, competitive intelligence, pricing analysis, identifying revenue pockets, understanding usage patterns and trends and supplyand demand-side analysis.
spacer
Rajiv Kalia
spacer
spacer
spacer
Ruchika Kakarya
spacer
spacer
spacer
Pooja Ganguly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

KITE’S CAR T-CELL THERAPY YESCARTA® (AXICABTAGENE CILOLEUCEL) FIRST IN EUROPE TO RECEIVE POSITIVE CHMP OPINION FOR USE IN SECOND-LINE DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA

Stockley Park, UK – 16 September, 2022 – Kite, a Gilead Company, today announces that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Yescarta® (axicabtagene ciloleucel) for adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. If approved, axicabtagene ciloleucel will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment. Although 60% of newly diagnosed LBCL patients will respond to their initial treatment, 40% will relapse or will not respond and need 2nd line treatment.
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement